Bluejay Diagnostics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Bluejay Diagnostics raised approximately $7.6 million in net proceeds from a June 2026 private placement, bringing cash to $9.6 million at Q2 2026 end (vs. $5.2 million at year-end 2025). The company completed targeted enrollment of 750 patients in its SYMON-II pivotal clinical study for Symphony IL-6 sepsis diagnostic and signed a US manufacturing contract. Cash runway estimated through Q2 2027; no regulatory approval yet obtained.
Why this rating
Financing represents ~370% of market cap; extends runway ~12 months. Pivotal study completion and manufacturing contract are critical de-risking milestones for micro-cap pre-revenue company. Significant relative to $2.6M scale but regulatory execution risk remains high.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.